Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice

Join us for a provocative program that includes interactive case discussions and a review of the data from a panel of renowned myeloma experts who will provide varied perspectives on new data, guideline changes, and expert recommendations for management of patients with multiple myeloma.

Interact with these international experts as they debate clinical questions and discuss how these challenges can affect therapeutic decisions faced by clinicians treating myeloma.

Friday Satellite Symposium preceding the 58th ASH Annual Meeting


Agenda

12:30 PM - 12:35 PM Welcome and Introduction
Brian G.M. Durie, MD, Program Director and Moderator 

12:35 PM - 1:05 PM Case Discussion 1
Diagnosing MM: When Should Treatment Be Initiated?
S. Vincent Rajkumar, MD

Faculty will discuss the controversies regarding the updated diagnostic criteria, patients who are not within diagnostic criteria but who are at risk, and when to treat patients with MM.

Faculty Panel Discussion and Audience Questions
Summary and Review of Key Take-Home Points

1:05 PM - 1:50 PM Case Discussion 2
Should We Be Using Risk-Adapted Therapy in Clinical Practice?
Shaji Kumar, MD, and Philippe Moreau, MD

Faculty will discuss the controversies regarding selecting treatment for newly diagnosed MM, including how to individualize therapy based on cytogenetic risk factors, patient age, and the presence of specific comorbidities.

Faculty Panel Discussion and Audience Questions
Summary and Review of Key Take-Home Points

1:50 PM - 2:20 PM Case Discussion 3
How Should We Use Maintenance for Patients in Clinical Practice?
Bruno Paiva, PhD, and Jesús F. San-Miguel, MD, PhD

Faculty will discuss the use of maintenance therapy for patients with MM as well as controversies regarding minimal residual disease and its use in guiding treatment decisions.

Faculty Panel Discussion and Audience Questions
Summary and Review of Key Take-Home Points

2:20 PM - 3:05 PM Case Discussion 4
How Do You Choose the Best Treatment Regimens for Relapsed/Refractory Disease?
Philippe Moreau, MD

Faculty will debate the issues regarding the optimal current salvage treatments and choosing between traditional agents or new options for patients with relapsed/refractory MM.

Faculty Panel Discussion and Audience Questions
Summary and Review of Key Take-Home Points

3:05 PM - 3:25 PM Where Are We Now and Where Are We Going With the Care of Patients With MM?

Brian G.M. Durie, MD, will lead a panel discussion on the current state of MM treatment.

3:25 PM - 3:30 PM Concluding Remarks
Brian G.M. Durie, MD, Program Director and Moderator


Learning Objectives
At the conclusion of the activity, participants should be able to:

  • Initiate therapy at the appropriate disease stage based on current evidence-based recommendations and multiple myeloma diagnosis criteria
  • Choose optimal treatment strategies for patients with newly diagnosed multiple myeloma
  • Use appropriate maintenance therapy approaches for multiple myeloma to maximize patient outcomes
  • Select optimal salvage therapies for patients with relapsed/refractory multiple myeloma based on available data, current guidelines, and expert recommendations
  • Implement use of newly emerging treatment options into clinical practice as new data, approvals, or indications become available

Accreditation Statement 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians. 

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. 

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Allison Hughes prior to the live event at ahughes@pimed.com

 

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower,  the International Myeloma Foundation, and Clinical Care Options LLC.  

This activity is supported by educational grants from  Amgen, Celgene Corporation, Karyopharm, Takeda Oncology, and The Binding Site.